June 2021—Bio-Techne Corp. has reached an agreement to acquire Asuragen for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.
Read More »Home >> Tag Archives: Bio-Techne
Bio-Techne to acquire Asuragen
March 9, 2021—Bio-Techne Corp. has reached an agreement to acquire Asuragen for an initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.
Read More »Bio-Techne launches cell and gene therapy portfolio
March 2019—Bio-Techne announced the launch of its cell and gene therapy portfolio.
Read More »Bio-Techne buys Exosome Diagnostics
July 2, 2018—Bio-Techne Corp. will acquire Exosome Diagnostics for $250 million in cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones. The deal is expected to close by early August.
Read More »Luminex, Bio-Techne expand partnership, 12/15
December 2015—Luminex and Bio-Techne have signed a new distribution and supply agreement through 2020.
Read More »